参考文献/References:
[1] Vindrieux D,Escobar P,Lazennec G.Emerging roles of chemokines in prostate cancer[J].Endocr Relat Cancer,2009,16(3):663-673.
[2] Chu H,Zhou H,Liu Y,et al.Functional expression of CXC chemokine receptor-4 mediates the secretion of matrix metallopro-teinases from mouse hepatocarcinoma cell lines with different lym-phatic metastasis ability[J].Int J Biochem Cell Biol,2007,39(1):197-205.
[3] Duda DG,Kozin SV,Kirkpatrick ND,et al.CXCL12(SDF1α)-CXCR4/CXCR7 pathway inhibition:an emerging sensitizer for an-ticancer therapies?[J].Clin Cancer Res,2011,17(8):2074-2080.
[4] Sun X,Cheng G,Hao M,et al.CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression[J].Cancer Metastasis Rev,2010,29(4):709-722.
[5] Feng Y,Broder CC,Kennedy PE,et al.HIV-1 entry cofactor func-tional cDNA cloning of a seven-transmembrane,G protein-coupled receptor[J].Science,1996,272(5263):827-877.
[6] Wu B,Chien EY,Mol CD,et al.Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antago-nists[J].Science,2010,330(6007):1066-1071.
[7] Domanska UM,Kruizinga RC,Nagengast WB,et al.A review on CXCR4/CXCL12 axis in oncology:no place to hide[J].Eur J Can-cer,2013,49(1):219-230.
[8] Burger JA,Kipps TJ.CXCR4:a key receptor in the crosstalk be-tween tumor cells and their microenvironment[J].Blood,2006,107(5):1761-1767.
[9] Ratajczak MZ,Zuba-Surma E,Kucia M,et al.The plieotropic ef-fects of the SDF-1-CXCR4 axis in organogenesis,regeneration and tumorigenesis[J].Leukemia,2006,20(11):1915-1924.
[10] Cojoc M,Peitzsch C,Trautmann F,et al.Emerging targets in cancer management:role of the CXCL12/CXCR4 axis[J].Onco Targets Ther,2013,6:1347-1361.
[11] Gerits N,Kostenko S,Shiryaev A,et al.Relations between the mi-togen-activated protein kinase and the cAMP-dependent protein kinase pathways:comradeship and hostility[J].Cell Signal,2008,20(9):1592-1607.
[12] Wojcechowskyj JA,Lee JY,Seeholzer SH,et al.Quantitative phos-phoproteomics of CXCL12(SDF-1) signaling[J/OL].PLoS One,2011,6(9):e24918[2013-08-28].http://www.plosone.org/arti-cle/info%3Adoi%2F10.1371%2Fjournal.pone.0024918.
[13] Princen K,Hatse S,Vermeire K,et al.Evaluation of SDF-1/CX-CR4-induced Ca2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometry[J].Cytometry A,2003,51(1):35-45.
[14] New DC,Wong YH.Molecular mechanisms mediating the G pro-tein-coupled receptor regulation of cell cycle progression[J].J Mol Signal,2007,2:2.
[15] Goel HL,Li J,Kogan S,et al.Integrins in prostate cancer progres-sion[J].Endocr Relat Cancer,2008,15(3):657-664.
[16] Romain B,Hachet-Haas M,Rohr S,et al.Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer[J].Mol Cancer,2014,13(1):58.
[17] Park BH,Kook S,Lee S,et al.An isoform of C/EBPβ,LIP,regu-lates expression of the chemokine receptor CXCR4 and modulates breast cancer cell migration[J].J Biol Chem,2013,288(40):28656-28667.
[18] McIver SC,Loveland KL,Roman SD,et al.The chemokine CX-CL12 and its receptor CXCR4 are implicated in human seminoma metastasis[J].Andrology,2013,1(3):517-529.
[19] 尹东,张佐,高素,等.趋化因子受体CXCR4及其配体CXCL12在口腔鳞状细胞增殖和迁移中的作用[J].华西口腔医学杂志,2013,31(1):8-12.
[20] Mo W,Chen J,Patel A,et al.CXCR4/CXCL12 mediate autocrine cell-cycle progression in NF1-associated malignant peripheral nerve sheath tumors[J].Cell,2013,152(5):1077-1090.
[21] Cavallaro S.CXCR4/CXCL12 in Non-Small-Cell Lung Cancer Metastasis to the Brain[J].Int J Mol Sci,2013,14(1):1713-1727.
[22] Liberman J,Sartelet H,Flahaut M,et al.Involvement of the CX-CR7/CXCR4/CXCL12 axis in the malignant progression of human neuroblastoma[J/OL].PloS one,2012,7(8):e43665[2013-08-28].http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjour-nal.pone.0043665.
[23] Cabioglu N,Sahin AA,Morandi P,et al.Chemokine receptors in advanced breast cancer:differential expression in metastatic dis-ease sites with diagnostic and therapeutic implications[J].Ann On-col,2009,20(6):1013-1019.
[24] Mimeault M,Batra SK.New advances on critical implications of tu-mor-and metastasis-initiating cells in cancer progression,treatment resistance and disease recurrence[J].Histol Histopathol,2010,25(8):1057-1073.
[25] Müller A,Homey B,Soto H,et al.Involvement of chemokine recep-tors in breast cancer metastasis[J].Nature,2001,410(6824):50-56.
[26] Woodard LE,Nimmagadda S.CXCR4-based imaging agents[J].J Nucl Med,2011,52(11):1665-1669.
[27] Yu S,Wang X,Liu G,et al.High Level of CXCR4 in triple-negative breast cancer specimens associated with a poor clinical outcome[J].Acta Med Okayama,2013,67(6):369-375.
[28] Gillies K,Wertman J,Charette N,et al.Anterograde trafficking of CXCR4 and CCR2 receptors in a prostate cancer cell line[J].Cell Physiol Biochem,2013,32(1):74-85.
[29] Kryczek I,Wei S,Keller E,et al.Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis[J].Am J Physiol Cell Physiol,2007,292(3):987-995.
[30] Teicher BA,Fricker SP.CXCL12(SDF-1)/CXCR4 pathway in can-cer[J].Clin Cancer Res,2010,16(11):2927-2931.
[31] Su L,Zhang J,Xu H,et al.Differential expression of CXCR4 is as-sociated with the metastatic potential of human non-small cell lung cancer cells[J].Clin Cancer Res,2005,11(23):8273-8280.
[32] Shim H,Oishi S,Fujii N.Chemokine receptor CXCR4 as a thera-peutic target for neuroectodermal tumors[J].Semin Cancer Biol,2009,19(2):123-134.
[33] Cheng M,Qin G.Progenitor cell mobilization and recruitment:SDF-1,CXCR4,α4-integrin,and c-kit[J].Prog Mol Biol Transl Sci,2012,111:243-264.
[34] 牛作兴,费立明,王长亮,等.CXCL12-CXCR4生物学轴在胰腺癌中的表达及其与血管生成的相关性[J].中华肿瘤杂志,2009,31(4):286-287.
[35] Hassan S,Buchanan M,Jahan K,et al.CXCR4 peptide antagonist inhibits primary breast tumor growth,metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model[J].Int J Cancer,2011,129(1):225-232.
[36] 刘静,郭华雄.趋化因子CXCL12/CXCR4生物轴在肿瘤中的研究进展[J].临床与实验病理学杂志,2010,26(4):477-480.
[37] Ramsey DM,McAlpine SR.Halting metastasis through CXCR4 in-hibition[J].Bioorq Med Chem,2013,23(1):20-25.
[38] Zhang XH,Wang Q,Gerald W,et al.Latent bone metastasis in breast cancer tied to Src-dependent survival signals[J].Cancer Cell,2009,16(1):67-78.
[39] Gassmann P,Haier J,Schlüter K,et al.CXCR4 regulates the early extravasation of metastatic tumor cells in vivo[J].Neoplasia,2009,11(7):651-661.
[40] Arigami T,Natsugoe S,Uenosono Y,et al.CCR7 and CXCR4 ex-pression predicts lymph node status including micrometastasis in gastric cancer[J].Int J Oncol,2009,35(1):19-24.
[41] Guo J,Lou W,Ji Y,et al.Effect of CCR7,CXCR4 and VEGF-C on the lymph node metastasis of human pancreatic ductal adenocarci-noma[J].Oncol Lett,2013,5(5):1572-1578.
[42] 杨文博,孔佩艳.以SDF-1/CXCR4为靶点治疗疾病的研究进展[J].医学综述,2010,16(21):3230-3232.
[43] Takaoka K,Hidaka S,Hashitani S,et al.Effect of a nitric oxide synthase inhibitor and a CXC chemokine receptor-4 antagonist on tumor growth and metastasis in a xenotransplanted mouse model of adenoid cystic carcinoma of the oral floor[J].Int J Oncol,2013,43(3):737-745.
[44] Nervi B,Ramirez P,Rettig MP,et al.Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100[J].Blood,2009,113(24):6206-6214.
[45] Burger JA,Peled A.CXCR4 antagonists:targeting the microenvi-ronment in leukemia and other cancers[J].Leukemia,2009,23(1):43-52.
[46] Kioi M,Vogel H,Schultz G,et al.Inhibition of vasculogenesis,but not angiogenesis,prevents the recurrence of glioblastoma after irra-diation in mice[J].J Clin Invest,2010,120(3):694-705.
[47] 师佳佳,贾晓辉,李晓红,等.雷帕毒素对骨髓瘤细胞RP-MI8226增殖、凋亡及趋化因子受体CXCR4表达的影响[J].中国实验血液学杂志,2009,17(2):385-389.
[48] DiPersio JF,Micallef IN,Stiff PJ,et al.Phase III prospective ran-domized double-blind placebo-controlled trial for plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mo-bilization and transplantation for patients with non-Hodgkin’s lym-phoma[J].J Clin Oncol,2009,27(28):4767-4773.
[49] Wang L,Huang T,Chen W,et al.Silencing of CXCR4 by RNA in-terference inhibits cell growth and metastasis in human renal can-cer cells[J].Oncol Rep,2012,28(6):2043-2048.
[50] Chen HY,Wang JM,Wang HY,et al.Effect of short hairpin RNA-induced CXCR4 silence on ovarian cancer cell[J].Biomed Pharma-cother,2012,66(7):549-553.
[51] De Clercq E.Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100,MozobilTM) and potential of other CXCR4 antagonists as stem cell mobilizers[J].Pharmacol Ther,2010,128(3):509-518.
[52] Jacobson O,Weiss ID,Szajek L,et al.64Cu-AMD3100-a novel imaging agent for targeting chemokine receptor CXCR4[J].Bioorg Med Chem,2009,17(4):1486-1493.
[53] Nimmagadda S,Pullambhatla M,Stone K,et al.Molecular imaging of CXCR4 receptor expression in human cancer xengografts with [64Cu]AMD3100 positron emission tomography[J].Cancer Res,2010,70(10):3935-3944.
[54] Weiss ID,Jacobson O,Kiesewetter DO,et al.Positron emission to-mography imaging of tumors expressing the human chemokine re-ceptor CXCR4 in mice with the use of 64Cu-AMD3100[J].Mol Imaging Biol,2012,14(1):106-114.
[55] De Silva RA,Peyre K,Pullambhatla M,et al.Imaging CXCR4 ex-pression in human cancer xenografts:evaluation of monocyclam 64Cu-AMD3465[J].J Nucl Med,2011,52(6):986-993.
[56] Nimmagadda S,Pullambhatla M,Pomper MG.Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT[J].J Nucl Med,2009,50(7):1124-1130.
[57] Tamamura H,Tsutsumi H,Fujii N.The chemokine receptor CX-CR4 as a therapeutic target for several diseases[J].Mini Rev Med Chem,2006,6(9):989-995.
[58] Hanaoka H,Mukai T,Tamamura H,et al.Development of a 111In-labeled peptide derivative targeting a chemokine receptor,CXCR4,for imaging tumors[J].Nucl Med Biol,2006,33(4):489-494.
[59] Jacobson O,Weiss ID,Kiesewetter DO,et al.PET of tumor CXCR4 expression with 4-18F-T140[J].J Nucl Med,2010,51(11):1796-1804.
[60] George GP,Stevens E,Aberg O,et al.Preclinical evaluation of a CXCR4-specific 68Ga-labelled TN14003 derivative for cancer PET imaging[J].Bioorg Med Chem,2014,22(2):796-803.
[61] Misra P,Lebeche D,Ly H,et al.Quantitation of CXCR4 expression in myocardial infarction using 99mTc-labeled SDF-1α[J].J Nucl Med,2008,49(6):963-969.
[62] Meincke M,Tiwari S,Hattermann K,et al.Near-infrared molecular imaging of tumors via chemokine receptors CXCR4 and CXCR7[J].Clin Exp Metastasis,2011,28(8):713-720.
[63] Demmer O,Gourni E,Schumacher U,et al.PET imaging of CXCR4 receptors in cancer by a new optimized ligand[J].Chem Med Chem,2011,6(10):1789-1791.
[64] Zhang XX,Sun Z,Guo J,et al.Comparison of 18F-labeled CXCR4 antagonist peptides for PET imaging of CXCR4 expression[J].Mol Imaging Biol,2013,15(6):758-767.
[65] Hartimath SV,Domanska UM,Walenkamp AM,et al.[99mTc]O2-AMD3100 as a SPECT tracer for CXCR4 receptor imaging[J].Nucl Med Biol,2013,40(4):507-517.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[3]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[4]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[5]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[6]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[7]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[8]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[9]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[10]程维维,王辉.促甲状腺激素受体与甲状腺癌关系的研究进展[J].国际放射医学核医学杂志,2012,36(2):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
CHENG Wei-wei,WANG Hui.Progress in the relationship of thyroid-stimulating hormone receptor and thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]